Author: Newsdesk

NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE:SLG), Manhattan’s largest office landlord, today announced that its board of directors has declared a monthly ordinary dividend of $0.2708 per share of common stock, which is the equivalent of an annualized dividend of $3.25 per share. The dividend is payable in cash on October 16, 2023 to shareholders of record at the close of business on September 29, 2023.

The board of directors also declared the regular quarterly dividend on the company’s Series I Preferred Stock for the period July 15, 2023 through October 14, 2023 of $0.40625 per share, which is the equivalent of an annualized dividend of $1.625 per share. The dividend is payable in cash on October 16, 2023 to shareholders of record at the close of business on September 29, 2023.

About SL Green Realty Corp.

SL Green Realty Corp., Manhattan’s largest office landlord, is a fully integrated real estate investment trust, or REIT, that is focused primarily on acquiring, managing and maximizing value of Manhattan commercial properties. As of June 30, 2023, SL Green held interests in 60 buildings totaling 33.1 million square feet. This included ownership interests in 28.8 million square feet of Manhattan buildings and 3.4 million square feet securing debt and preferred equity investments.

Forward Looking Statement

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are intended to be covered by the safe harbor provisions thereof. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future, are forward-looking statements. Forward-looking statements are not guarantees of future performance and actual results or developments may differ materially, and we caution you not to place undue reliance on such statements. Forward-looking statements are generally identifiable by the use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “project,” “continue,” or the negative of these words, or other similar words or terms.

Forward-looking statements contained in this press release are subject to a number of risks and uncertainties, many of which are beyond our control, that may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by forward-looking statements made by us. Factors and risks to our business that could cause actual results to differ from those contained in the forward-looking statements include the risks and uncertainties described in our filings with the Securities and Exchange Commission. Except to the extent required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information or otherwise.

SLG – DIV

PRESS CONTACT
[email protected]

FLORHAM PARK, N.J., Sept. 18, 2023 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to iopofosine I 131, the company’s lead small-molecule drug candidate, for Waldenstrom’s macroglobulinemia (WM) in patients who have received two or more prior treatment regimens.

The PRIME program aims to optimize development plans and speed up evaluation of medicines that may offer a major therapeutic advantage over existing treatments or benefit patients without treatment options. These medicines are considered priority medicines by the EMA and are intended to reach patients earlier. To be accepted for PRIME, new therapies must demonstrate the potential to significantly address an unmet medical need in clinical trials.

“PRIME designation from the EMA further underscores our confidence in iopofosine I 131 to provide a differentiated and highly needed new treatment option for patients with WM,” said James Caruso, president and CEO of Cellectar. “We expect to release top-line data from the CLOVER-WaM pivotal trial in the fourth quarter of 2023 and submit our NDA in March, 2024. With PRIME designation now in hand we look forward to advancing our EU strategy to bring this potential targeted treatment option to patients in the US and EU as quickly as possible.”

The U.S. Food and Drug Administration (FDA) has granted Cellectar’s lead asset iopofosine I 131, a small-molecule Phospholipid Drug Conjugate™ (PDC) designed to provide targeted delivery of iodine-131 (radioisotope), Fast Track Designation for WM patients having received two or more prior treatment regimens, as well as relapsed (or refractory) multiple myeloma and relapsed (or refractory) diffuse large B-cell lymphoma (DLBCL). The company expects to complete our ongoing Phase 2b WM pivotal trial (NCT02952508) in the second half of 2023 and assuming an FDA Priority Review and approval, remains on target for a 2024 US product launch.

About
Cellectar
Biosciences,
Inc.

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.

The company’s product pipeline includes lead asset iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.

Forward-Looking
Statement
Disclaimer

This news release contains forward-looking statements. You can identify these statements by our use of words such as “may,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” “continue,” “plans,” or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes including our expectations regarding the WM CLOVER-WaM pivotal trial. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to maintain orphan drug designation in the United States for iopofosine, the volatile market for priority review vouchers, our pharmaceutical collaborators’ ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2022, and our Form 10-Q for the quarter ended June 30, 2023. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

Contacts

Investors:

Monique Kosse
LifeSci Advisors
212-915-3820
[email protected]

Media:

Claire LaCagnina
Bliss Bio Health
315-765-1462
[email protected] 

Miami, FL, Sept. 18, 2023 (GLOBE NEWSWIRE) — Blue Star Foods
Corp
., (“
Blue Star
,
”
the
“
Company,” “we,” “our” or “us”)
(
N
ASDAQ
:

BSFC

), an integrated Environmental, Social, and Governance (ESG) sustainable seafood company with a focus on Recirculatory Aquaculture Systems (RAS), is pleased to announce that it has allocated $2,573,142 from its [recently closed equity raise on september 7^th ] to repay and terminate the largest of the three Convertible Notes outstanding to The Lind Partners to reduce total debt and improve the Company’s balance as it positions itself for future growth initiatives.

John Keeler, Chairman and CEO of Blue Star Foods, commented, “The Lind Partners has been a great financial partner that provided growth capital when we needed it to buy additional inventory and strengthen our balance sheet. With the largest Lind convertible note retired, Blue Star can use its operational cash flow to further advance on its SoftShell crab RAS farm new site in Beaufort, South Carolina”

A
bout Blue Star Foods Corp
.
(N
ASDAQ
:

BSFC

)

Blue Star Foods Corp. an integrated Environmental, Social, and Governance (ESG) sustainable seafood company with a focus on Recirculatory Aquaculture Systems (RAS) that processes, packages and sells high-value seafood products. The Company believes it utilizes best-in-class technology, in both resource sustainability management and traceability, and ecological packaging. The Company also owns and operates the oldest continuously operating Recirculating Aquaculture System (RAS) full grow-out salmon farm in North America. The company is based in Miami, Florida, and its corporate website is: https://bluestarfoods.com

F
orward
–
Looking
S
tatements
:

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:

[email protected]

VANCOUVER, British Columbia, Sept. 18, 2023 (GLOBE NEWSWIRE) — AgriFORCE Growing Systems Ltd. (“the Company”) (NASDAQ: AGRI; AGRIW), an intellectual property (IP)-focused agtech company, today announced the commercial launch and first purchase order for its AgriFORCE-RCS Hydroxyl device with Commercializadora DESICO (“DESICO”), a leading distributor of AC, heating and air ventilation systems. The AgriFORCE RCS-Hydroxyl device, developed by Radical Clean Solutions Ltd (RCS), is a chemical-free technology proven to eliminate pathogens, mold, mildew, and volatile organic compounds (VOCs) in food production facilities and indoor farms.

AgriFORCE Interim CEO, Richard Wong commented, “This first purchase order marks a major milestone in the commercial rollout of the AgriFORCE-RCS Hydroxyl devices. We have conducted extensive analysis and worked closely with Radical Clean Solutions Ltd. (RCS), the inventor and developer of the technology, to customize the technology for the specific needs of customers in the controlled environment agriculture (CEA) and food manufacturing industries. The patent-pending system seeks out and destroys both airborne and surface-based mold, bacteria, virus, and VOCs, as well as other pathogens and pollutants in real-time. By reducing mold and VOCs, we expect to have a dramatic impact on the bottom line of our customers through reducing food spoilage. In fact, according to Food and Agricultural Organization (FAO), it is estimated that mycotoxin (mold) affects nearly 25% of the world’s crops. We believe this is just the first of many orders with DESICO and in the Mexico market with vast acres of greenhouses as potential clients, and a large food manufacturing industry. We currently have units in testing within greenhouses in the United States and expect test results soon. We also look forward to expanding into new markets around the world.”

ABOUT AGRIFORCE

AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI; AGRIW) is an AgTech company focused on building an integrated AgTech platform that combines the best technology, intellectual property, and knowledge to solve an urgent problem – providing the best solutions to help drive sustainable crops and nutritious food for people around the world. The AgriFORCE vision is to be a global leader in delivering plant-based foods and products through an advanced and sustainable AgTech platform that makes positive change in the world—from seed to table. Additional information about AgriFORCE is available at: www.agriforcegs.com.

Follow AgriFORCE on Twitter: 

@agriforcegs


Follow AgriFORCE on Facebook: 

AgriFORCE Growing Systems Ltd.


Connect with AgriFORCE on LinkedIn: 

AgriFORCE Growing Systems Ltd.

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in our filings with the Securities and Exchange Commission and elsewhere. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release. This announcement is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities of the issuer. Any offer to sell or solicitation of an offer to buy securities of the issuer may only be made pursuant to a valid prospectus pursuant to an effective registration statement or pursuant to a valid exemption from registration under the Securities Act of 1933, as amended and the rules and regulations promulgated thereunder.

Company Contact:
Ian Pedersen
Tel: (604) 757-0952
Email: [email protected]  

Investor Relations:

Crescendo Communications, LLC
David Waldman/Alexandra Schilt
Tel: (212) 671-1021
Email: [email protected]

PHILADELPHIA, PA, Sept. 18, 2023 (GLOBE NEWSWIRE) — FTAC Emerald Acquisition Corp. (NASDAQ:EMLD) (the “Company”), a blank-check company formed for the purpose of acquiring or merging with one or more businesses, announces that the special meeting in lieu of annual meeting of stockholders (the “Meeting”) scheduled to be held on September 18, 2023 at 4:30 pm Eastern Time will be postponed until 4:30 pm Eastern Time on Tuesday, September 19. As previously announced, the Meeting will occur virtually at https://www.cstproxy.com/ftacemeraldacquisition/2023. The Meeting is being held for the purposes of considering and voting on (i) an extension amendment to the Company’s Amended and Restated Certificate of Incorporation, (ii) an extension amendment to the Investment Management Trust Agreement and (iii) an Adjournment Proposal, each as described in the Company’s amended definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on August 31, 2023. The price for any shares of Class A common stock properly redeemed in connection with the Meeting is estimated to be approximately $10.47 per share.

The proxy card included with the previously distributed proxy materials will not be updated to reflect the adjournment and may continue to be used to vote shares in connection with the Meeting. There is no change to the location, record date, purpose or any of the proposals to be acted upon at the Meeting. Stockholders who have already voted and do not wish to change their vote do not need to vote again.

Important Information and Where to Find It

The Company has mailed to its stockholders of record as of August 22, 2023 a definitive proxy statement (the “Proxy Statement”). Investors and security holders of the Company are advised to read the Proxy Statement because it contains important information about the Meeting and the Company. Investors and security holders of the Company may also obtain a copy of the Proxy Statement, as well as other relevant documents that have been or will be filed by the Company with the SEC, without charge and once available, at the SEC’s website at www.sec.gov or by directing a request to: FTAC Emerald Acquisition Corp., 2929 Arch Street, Suite 1703, Philadelphia, PA 19104.

Participants in the Solicitation

The Company and certain of its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from the Company’s stockholders in respect of the Proposals to be considered and voted on at the Meeting. Information concerning the interests of the directors and executive officers of the Company is set forth in the Proxy Statement, which may be obtained free of charge from the sources indicated above.

No Offer or Solicitation

This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s annual report on Form 10-K filed with the SEC and subsequent reports filed with the SEC, as amended from time to time. Copies of these documents are available on the SEC’s website, at www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact Information:

FTAC Emerald Acquisition Corp.
[email protected]

ATLANTA, Sept. 18, 2023 (GLOBE NEWSWIRE) — Trust Stamp (Nasdaq: IDAI), the Privacy-First Identity Company^TM providing AI-powered trust and identity services used globally across multiple sectors has announced the launch of its Tap-In Band™, a wrist-worn, tamper resistant, hypoallergenic NFC band that facilitates discrete check-in by, and communication with, participants in community based supervision programs.

The Tap-In Band leverages the GPS and NFC technologies in the user’s own mobile phone and allows the user to verify their well-being and location by tapping the band to the phone, gaining direct access to a personalized web portal with messaging and two-way audio visual communications. The use of the Tap-In Band augments facial biometric authentication using the phone’s camera and Trust Stamp holds provisional patent #63/581,409 from the US Patent and Trademark Office covering multi-factor authentication using a tamper proof band and biometric authentication.

Unlike existing ankle and wrist worn technologies, The Tap-In Band has no battery, removing perennial concerns about battery failure and the inconvenience of charging, and does not itself contain GPS tracking technology thereby reducing user apprehension regarding intrusive monitoring. Removal of the Band results in the Band permanently notifying tampering even if competently repaired.

The Tap-In Band and associated biometric processes utilize Trust Stamp’s patented IT² identity tokenization processes that allow users to biometrically authenticate without the need to store biometric images or templates.

Gareth N. Genner, Trust Stamp’s Chief Executive Officer said, “The Tap-In Band is the result of three years of market discovery and development and is a game-changer.  The band is battery-free and has a fitness band-styled design that provides secure authentication without imposing embarrassment or discomfort. We are not publicly releasing images of the customizable aesthetic design but I will say that the Band is available in a variety of colors with optional design features that ensure that the underlying use-case is not obvious to an onlooker.

The use of our IT² identity tokenization, combined with data flows that do not require any data to be received or processed by Trust Stamp or any other vendor, ensure that the legitimate privacy and safety concerns that are raised by legacy technologies are removed with the Tap-In Band. While the Tap-In Band can be used for continual monitoring programs, we believe that the highest and best use is to support programs that require scheduled or randomly triggered check-ins.”

Genner went on to say, “Alternative to Detention programs are not only more humane than incarceration but also cost society a fraction of the cost while having a high success rate. That said, although over $440 million is spent on such programs in the United States each year, their expansion is limited, at least in part, by budgetary constraints. The Tap-In Band, combined with the user’s own mobile device offers all of the utility of devices that are up to 100x the capital and operational costs and the technology can be quickly integrated into a wide range of community monitoring programs with minimal capital investment.”

Inquiries:

Trust Stamp                                                   Email: [email protected]

Gareth N. Genner

Chief Executive Officer         

About Trust Stamp

Trust Stamp the Privacy-First Identity CompanyTM, is a global provider of AI-powered identity services for use in multiple sectors including banking and finance, regulatory compliance, government, real estate, communications, and humanitarian services. Its technology empowers organizations with advanced biometric identity solutions that reduce fraud, protect personal data privacy, increase operational efficiency, and reach a broader base of users worldwide through its unique data transformation and comparison capabilities.

Located in six countries across North America, Europe, Asia, and Africa, Trust Stamp trades on the Nasdaq Capital Market (Nasdaq: IDAI). The company was founded in 2016 by Gareth Genner and Andrew Gowasack.

Safe Harbor Statement: Caution Concerning Forward-Looking Remarks 

All statements in this release that are not based on historical fact are “forward-looking statements” including within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The information in this announcement may contain forward-looking statements and information related to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events-based information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events. 

GREENWICH, Conn., Sept. 18, 2023 (GLOBE NEWSWIRE) — XPO (NYSE: XPO), a leading provider of freight transportation in North America, announced today that three of its business leaders have been named recipients of the prestigious 2023 Women in Supply Chain award from Supply & Demand Chain Executive magazine. 

The award recipients are:

Rachel Jorgenson, vice president, Sales, East Division, who led the development of XPO’s internal key performance indicator tracking system, providing a simplified view of the sales team’s most significant KPIs and helping to track growth in their books of business.

Sonja Kelly, director, Human Resources, whose expertise and leadership were instrumental in helping drive the improvements in quality and service at XPO, along with higher employee satisfaction rates. 

Kimberly Torres, senior service center manager, whose steadfast leadership and mentorship have helped drive positive change in our Florida operations. Her accomplishments in the field have also been recognized by the Women in Trucking Association with a 2023 Top Woman to Watch in Transportation award.

“We’re proud of Rachel, Sonja and Kimberly for earning this top recognition for their important contributions to XPO and the supply chain industry,” said Carolyn Roach, chief human resources officer, XPO. “Leading by example, our three award recipients are demonstrating the wide range of fulfilling career opportunities at XPO and how women can make an impact within our industry.”  

Supply & Demand Chain Executive magazine established the Women in Supply Chain award to recognize female supply chain leaders whose accomplishments, mentorship and examples set a foundation for women in all levels of a company’s supply chain network.    

About XPO 

XPO, Inc. (NYSE: XPO) is one of the largest providers of asset-based less-than-truckload (LTL) transportation in North America, with proprietary technology that moves goods efficiently through its network. Together with its business in Europe, XPO serves approximately 49,000 customers with 562 locations and 37,000 employees. The company is headquartered in Greenwich, Conn., USA. Visit xpo.com for more information, and connect with XPO on Facebook, X, LinkedIn, Instagram and YouTube.

Media Contact

Karina Frayter 
203-484-8303
[email protected]

Wilmington, DE, Sept. 18, 2023 (GLOBE NEWSWIRE) — Today, Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology company, announced it will showcase new products from its recent acquisitions of Novastep® and the external fixation assets of D.N.E., LLC, along with its new, organically developed Evolve34™ Lapidus Instrumentation, and the new “STAR+ Experience,” Enovis’ Total Ankle System plus patient specific instrumentation (PSI), at the American Orthopaedic Foot & Ankle Society® (AOFAS) annual meeting in Louisville, Kentucky from September 20-23, 2023.

“Enovis™ is dedicated to improving patient outcomes by introducing technologies that solve real issues in the foot and ankle industry,” stated Gary Justak, President and General Manager of Enovis™ Foot and Ankle. “Our recent acquisition of Novastep® and the Pecaplasty® Percutaneous Bunion Correction System will drive outcome improvements with an underserved patient population, and the MIS bunion surgery provides efficiency in the OR for the surgeon, while improving patient recovery times with less pain.^1,2,3”

Other offerings being showcased for the first time will be Evolve34™, a bunion solution for Lapidus correction that allows surgeons to dial in deformity correction and select a hardware construct specific for the patient’s needs. Additionally, Enovis will be introducing the all new EF1 External Fixation product line, complimenting the flagship DynaNail® and DynaClip™ offerings in the hindfoot segment.

Enovis™ will also highlight products from its foot and ankle continuum of care including:

• 
  Centrolock® System
  – MIS Bunion Correction
• 
  STAR® Ankle
  PSI – Patient Specific Instrumentation for Total Ankle Replacement
• 
  Aircast® AirSelect™ Elite
  Walking Boot
• 
  Airlift™ PTTD
  A versatile stirrup design that aids in the treatment of posterior tibial tendon dysfunction (PTTD)
• 
  Regeneration OL1000
  
  ™ Bone Stimulation Device

AOFAS attendees have opportunities throughout the week to experience these product offerings firsthand.

• Visit Enovis Booth #313 in the exhibit hall.
• Register for a special Wednesday evening event, Meet us at the Winner’s Circle, September 20^th from 6:30 – 9:30 p.m. Registration links and more information can be found here: https://www.djoglobal.com/aofas
• Educational event to hear Tyler Gonzalez, MD, MBA* present “Biomechanical Performance of Static Compression Devices Compared to NiTiNOL Compression Devices in Simulated First Metatarsophalangeal Joint Arthrodesis” on September 23 at 8:00 a.m. This presentation is part of the AOFAS Foot and Ankle Papers Session 5A: Forefoot in Ballroom A on the main level.

*Dr. Gonzalez is a paid consultant of Enovis.

CRO-2023-0229, MK-10279

About Enovis

Enovis Corporation (NYSE: ENOV) is an innovation-driven, medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit www.enovis.com.

1. Lee M, Walsh J, Smith MM, Ling J, Wines A, Lam P. Hallux valgus correction comparing percutaneous chevron/Akin (PECA) and open scarf/Akin osteotomies. Foot Ankle Int. 2017;38(8):838-846. doi:10.1177/1071100717704941
2. Maffulli N, Longo UG, Oliva F, Denaro V, Coppola C. Bosch osteotomy and scarf osteotomy for hallux valgus correction. Orthop Clin North Am. 2009;40(4):515-524. doi:10.1016/j.ocl.2009.06.003
3. Lam P, Lee M, Xing J, Di Nallo M. Percutaneous surgery for mild to moderate hallux valgus. Foot Ankle Clin. 2016;21(3):459-477. doi:10.1016/j.fcl.2016.04.001

Media Contact:

Erica Mellema
Enovis
(269) 377-2937
[email protected]

Attachment

• Enovis Foot & Ankle at AOFAS 2023